Merck Set to Acquire Terns Pharma for $6 Billion in Cash, Says FT

• The transaction is valued at roughly $6 billion in all-cash consideration
• Negotiations between Merck and Terns Pharma are at an advanced stage with a deal potentially closing in the coming days
• Both Merck and Terns Pharma declined to comment on the reported acquisition when contacted by Reuters

Merck Set to Acquire Terns Pharma for $6 Billion in Cash

Pharmaceutical giant Merck is in advanced negotiations to acquire biotech company Terns Pharma in an all-cash transaction valued at approximately $6 billion, according to a Financial Times report citing people familiar with the matter.

Key Details:

• Deal Structure: All-cash acquisition
• Transaction Value: Approximately $6 billion
• Timeline: Discussions are at an advanced stage, with a deal potentially closing within days
• Status: Neither Merck nor Terns Pharma has officially commented on the reported negotiations

Market Context:

This acquisition would represent a significant consolidation move in the biotechnology sector, as major pharmaceutical companies continue seeking to bolster their pipelines through strategic acquisitions. The deal underscores Merck's commitment to expanding its therapeutic portfolio and accessing innovative biotech assets.

Implications:

For Merck, the acquisition would provide access to Terns Pharma's pipeline and technology platform, potentially strengthening its competitive position in targeted therapeutic areas. The $6 billion price tag reflects the premium valuations currently commanded by promising biotech assets in the pharmaceutical industry.

The transaction comes amid ongoing consolidation trends in the healthcare sector, where established pharmaceutical companies are actively pursuing smaller biotech firms with promising drug candidates or novel technology platforms to supplement their own research and development efforts.

Investors and analysts will be watching for official announcements from both companies regarding deal terms, strategic rationale, and expected timeline for completion, pending regulatory approvals and customary closing conditions.